Busulphan
Wolman Disease
Masonic Cancer Center, University of MinnesotaPhase 2/3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Wolman Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Sebelipase Alfa Alexion Pharmaceuticals, Inc. | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Clofarabine Masonic Cancer Center, University of Minnesota | Phase 2 | B |
Evomela Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 10 →
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →